Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2022-11-27 AGM Information
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
AGM Presentation and Chairman's Address 39 pages 2.6MB
AGM Information Classification · 100% confidence The document is titled 'Annual General Meeting November 28, 2022' and contains detailed agenda items typical of an AGM, including the Chairman's address, CEO address, resolutions to be voted on (such as remuneration report adoption, re-election of a director, increased placement capacity, and amendment to the constitution), proxy voting results, and Q&A instructions. It also includes strategic and operational highlights and business updates presented during the meeting. The content is consistent with materials shared during an Annual General Meeting rather than a full annual report or other filing types. The length (15,000 characters) and detailed meeting content confirm it is not a brief announcement or a report publication notice. Therefore, the document is best classified as AGM Information (AGM-R).
2022-11-27 English
Results of AGM 3 pages 327.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX Market Announcement titled 'Results of Annual General Meeting' for Genetic Technologies Limited, dated 28 November 2022. It provides detailed voting results for resolutions passed at the AGM, including adoption of the remuneration report, re-election of a director, approval of increased placement capacity, and amendment to the constitution. The document references ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to disclosure of voting results. The content is focused on the official announcement of shareholder voting outcomes rather than the AGM materials themselves or the full annual report. The document length is 4846 characters, which is concise and typical for a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-27 English
GTG Webinar on Risk Assessment Tests for Serious Disease 2 pages 168.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement about a webinar featuring an interview on risk assessment tests for serious diseases, specifically focusing on geneType testing and cancer risk assessment. It includes details about the webinar date, time, registration link, and background information about the company and the interviewee. There is no financial data, no report or results announcement, no regulatory filing, no management or board changes, no capital or financing update, and no voting or dividend information. The document is essentially an event announcement and investor relations communication without substantive financial or regulatory content. Therefore, it does not fit into categories like Annual Report, Earnings Release, Interim Report, or Regulatory Filings. Given the nature of the content as a market announcement about an upcoming webinar, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-11-09 English
Change of Director's Interest Notice 7 pages 510.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings and interests of company directors, including the number of securities held before and after changes, nature of changes, and dates. The content is focused on personal share transactions by company directors, specifically reporting disposals and expiries of unlisted options. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of director share transactions, which aligns with the definition of Director's Dealing filings.
2022-11-08 English
Genetype for Ovarian Cancer published in European Journal 2 pages 225.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited about the publication of a validation study on their geneType ovarian cancer test in a scientific journal. It highlights study findings and the significance of the test but does not contain financial statements, management discussion, or regulatory filings. The document is a public announcement of a scientific publication and study results, not a financial report, regulatory filing, or management report. It is not an earnings release, annual report, or any other financial or governance document. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2022-11-08 English
Notification of cessation of securities - GTG 4 pages 24.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired without exercise or conversion. It details the number of securities ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement of changes in the company's issued capital related to securities, not a full financial report or detailed analysis. It fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as cessation of securities.
2022-11-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.